|
|
|
|
 |
 |
AstraZeneca Press Releases |
 |
| Company Profile |
| AstraZeneca |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers - Major |
| Employees |
Unknown |
|
Contact Info |
AstraZeneca plc
15 Stanhope Gate
London,
W1K 1LN
United Kingdom
Phone: 44 20 7304 5000
Fax: 44 20 7304 5151
Web Site: http://www.astrazeneca.com
|
| AstraZeneca Historical Share Price |
|
|
|
| Company Summary |
| AstraZeneca PLC discovers, develops, manufactures, and markets prescription pharmaceuticals in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the maintenance treatment of asthma in patients. The company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages out-patient cancer centers in the United States. AstraZeneca markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, or local representative offices. It has strategic alliances with AtheroGenics, Inc.; Pozen, Inc.; Bristol-Myers Squibb Company; Cambridge Antibody Technology Group plc; KuDOS Pharmaceuticals Limited; WuXi Pharmatech Co., Ltd; and ChemBridge; and a strategic partnership with Peking University Third Hospital. The company also has collaborations with Palatin Technologies, Inc.; Schering AG; Protherics PLC; Targacept, Inc.; Abgenix; Dyax Corp.; Abbott Laboratories; BioFocus DPI; Silence Therapeutics plc; Argenta Discovery Limited; Effector Cell Institute; Cancer Research Technology Limited; Beatson Institute for Cancer Research; and Myriad Genetics, Inc. It has an agreement with Biovator AB to co-operate on the development of an in vitro-test that identifies potential allergens. AstraZeneca was founded in 1992. It was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999. The company is headquartered in London, the United Kingdom. |
|
|
|
|
30th October, 2008
AstraZeneca PLC Third Quarter and Nine Months Results 2008
Download the narrative and the figures.
|
21st October, 2008
AstraZeneca Announces European SEROQUEL XR Submission for the Treatment of Generalised Anxiety Disorder
AstraZeneca today announced its submission of SEROQUEL XR (quetiapine fumarate extended release tablets) to European regulatory authorities seeking approval for both short-term and maintenance treatment of Generalised Anxiety Disorder (GAD). This is the first time approval has been sought in Europe for an atypical antipsychotic medicine for the treatment of GAD ...
|
17th October, 2008
AstraZeneca and POZEN Informed of FDA Internal Review of Gastric Ulcers as a Primary Endpoint in Trials
AstraZeneca and POZEN Inc., co-development partner for the investigational compound PN 400, have announced today that the U.S. Food and Drug Administration (FDA) has informed POZEN that it is conducting an internal review on the acceptability of endoscopic gastric ulcers as a primary endpoint in clinical studies ...
|
10th October, 2008
FDA Approves AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex ...
|
24th September, 2008
US Court Denies Teva’s Motion For Summary Judgment In Pulmicort Respules Patent Litigation
AstraZeneca today announced that the US District Court for the District of New Jersey has denied Teva’s Motion for Summary Judgment of no infringement in the PULMICORT RESPULES (budesonide inhalation suspension) patent litigation ...
|
16th September, 2008
AstraZeneca and Targacept Announce Top-Line Results From Phase IIb Study of AZD3480 in Alzheimer’s Disease
Results inconclusive, as primary outcome measure not statistically significant for either donepezil or AZD3480; results impacted by improvement in placebo groupImprovements shown on secondary outcome measures ADCS-CGIC and MMSEOverall safety and tolerability profile comparable to placebo, with fewer GI-related AEs than donepezilNext steps include further analysis of full dataset and planned discussions with leading medical expertsAstraZeneca and Targacept, Inc ...
|
12th September, 2008
AstraZeneca PLC Appoints New Non-Executive Director
AstraZeneca today announced that Rudy Markham is to join the Board of Directors as a Non-Executive Director with immediate effect. Rudy Markham was formerly Chief Financial Officer of Unilever. He is currently a Non-Executive Director of Legal and General Group Plc, Standard Chartered PLC and United Parcel Service, Inc ...
|
9th September, 2008
New Data for Investigational Diabetes Drug Saxagliptin Demonstrates Potential for Type 2 Diabetes Treatment
New data presented for the first time at EASD 2008Saxagliptin with metformin as initial combination therapy lowered A1CImprovements demonstrated across key measures of glucose control studied in treatment-naïve people with type 2 diabetesResults from a 24-week Phase III study presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that saxagliptin, an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme, in development by Bristol-Myers Squibb Company and AstraZeneca, when used in combination with metformin as an initial therapy, produced reductions across all key measures of glucose control studied [glycosylated hemoglobin level (A1C), fasting plasma glucose (FPG) and postprandial glucose (PPG)] in treatment-naïve people with inadequately controlled type 2 diabetes, compared with monotherapy with saxagliptin or metformin ...
|
8th September, 2008
Saxagliptin Improved Key Measures of Glucose Control When Added to a Sulphonylurea or Thiazolidinedione in People with Inadequately Controlled Type 2 Diabetes
Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrate that saxagliptin produced reductions across all key measures of glucose control studied [glycosylated hemoglobin level (A1C), fasting plasma glucose (FPG) and postprandial glucose (PPG)] when added to a sulphonylurea (SU) or a thiazolidinedione (TZD) in people with inadequately controlled type 2 diabetes, compared with placebo added to either an increased dose of SU or a stable dose of a TZD ...
|
14th August, 2008
AstraZeneca and Abbott Expand Relationship to Include Co-Promotion of CRESTOR®
AstraZeneca and Abbott announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR® (rosuvastatin calcium), a medication used along with diet to reduce high cholesterol.Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote CRESTOR alongside AstraZeneca in the United States, excluding Puerto Rico ...
|
|
|
|
Next 10 » |
|
|
|
|
